1 / 1

BP ≥ 130/80 - ≤ 150/90

Finish study. Responders (BP < 130/80). Monotherapy * Eprosartan 600 vs. Ramipril 5. BP ≥ 130/80 - ≤ 150/90. Non-responders (BP ≥ 130/80). Double-combination therapy * Eprosartan/HCTZ 600/12.5 vs. Ramipril/HCTZ 5/12.5. Hypertension

deidra
Download Presentation

BP ≥ 130/80 - ≤ 150/90

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Finish study Responders (BP < 130/80) Monotherapy* Eprosartan 600 vs. Ramipril 5 BP ≥ 130/80 - ≤ 150/90 Non-responders (BP ≥ 130/80) Double-combination therapy* Eprosartan/HCTZ 600/12.5 vs. Ramipril/HCTZ 5/12.5 Hypertension + DM type 2 Responders (BP < 130/80) BP > 150/90 - ≤ 179/109 Double-combination therapy* Eprosartan/HCTZ 600/12.5 vs. Ramipril/HCTZ 5/12.5 Non-responders (BP≥ 130/80) Triple-combination therapy* Epro./HCTZ/Moxo 600/12.5/0.4 vs. Ramipril/HCT/Moxo 5/12.5/0.4 R 1 week 2 weeks 4 weeks 8 weeks Screening Placebo Mono- or double-combination therapy Combination therapy with two-, adjusted to severity of hypertension respectively three agents in non-responders of the four initial arms * - Eprosartan and Ramipril to be administered together with corresponding placebo (double-dummy technique).

More Related